+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ovarian Cancer Treatment Market - Forecasts from 2019 to 2024

  • ID: 4801619
  • Report
  • 106 pages
  • Knowledge Sourcing Intelligence LLP
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Clovis Oncology
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen Inc.
  • MORE
The ovarian cancer treatment market is projected to grow at a CAGR of 7.02% to reach US$2.505 billion by 2024. The ovarian cancer treatment market is expected to grow at a fast pace during the forecast period due to the growing incidence of ovarian cancer among women worldwide. According to the American Cancer Society, around 22,530 new cases of ovarian cancer will be diagnosed in 2019 and around 13,980 deaths are likely to occur in the same year. Region-wise, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions. The growing number of clinical trials have improved the chances of new innovations for targeted cancer treatment, emanating the market growth during the forecast period. Growing awareness among women has further led to early diagnosis, further leading to the treatment of ovarian cancer at an early stage, when diagnosed, thus, improving the survival rate of the patients. Currently available treatments include surgery, chemotherapy, radiation therapy, and hormonal therapy.

Drivers

Rising ovarian cancer incidence
Growing number of clinical trials for new innovations
Increasing health expenditure

Restraints

High cost of cancer treatment

Industry Update

According to the Biospectrum news on 21st June 2019, the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) entered into a collaboration with AstraZeneca for enhancing the quality in cancer for people suffering from advanced ovarian cancer.

Predictive Oncology, previously known as Precision Therapeutics, in April 2019, announced that it has entered into a collaboration with Helomics and Viome to study the link between the gut microbiome and ovarian cancer.

Major industry players profiled as part of the report are Sotio (Member of PPF Group), Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, TESARO, Inc., Clovis Oncology, AbbVie Inc., Oasmia Pharmaceutical AB, ImmunoGen Inc., and Boehringer Ingelheim GmbH.

Segmentation

The ovarian cancer treatment market has been analyzed through the following segments:

By Diagnosis
Blood Tests
Imaging Tests
Laparoscopy
Colonoscopy
Others

By Treatment
Surgery
Radiation Therapy
Chemotherapy
Hormone Therapy
Clinical Trials

By Geography

North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Clovis Oncology
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen Inc.
  • MORE
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

3. KEY FINDINGS

4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By region
4.6. Product Pipeline
4.7. Innovations

5. OVARIAN CANCER TREATMENT MARKET BY DIAGNOSIS
5.1. Blood Tests
5.2. Imaging Tests
5.3. Laparoscopy
5.4. Colonoscopy
5.5. Others

6. OVARIAN CANCER TREATMENT MARKET BY TREATMENT
6.1. Surgery
6.2. Radiation Therapy
6.3. Chemotherapy
6.4. Hormone Therapy
6.5. Clinical Trials

7. OVARIAN CANCER TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others

8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES
9.1. Sotio (Member of PPF Group)
9.2. Pfizer Inc.
9.3. AstraZeneca
9.4. F. Hoffmann-La Roche Ltd
9.5. TESARO, Inc.
9.6. Clovis Oncology
9.7. AbbVie Inc.
9.8. Oasmia Pharmaceutical AB
9.9. ImmunoGen Inc.
9.10. Boehringer Ingelheim GmbH
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Sotio (Member of PPF Group)
  • Pfizer Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • TESARO, Inc.
  • Clovis Oncology
  • AbbVie Inc.
  • Oasmia Pharmaceutical AB
  • ImmunoGen Inc.
  • Boehringer Ingelheim GmbH
Note: Product cover images may vary from those shown
5 of 4

The research study is based on the publisher's proprietary research model. The process involves sourcing of information from various industry experts, key professionals, decision-makers and various other stakeholders along with the validation of the responses received from the vast in-house database and premium paid databases. Publicly available sources were also taken into consideration for the final market estimates and forecast for the segments and sub-segments.

The first phase of the research process is the identification of key industry leaders, experts, decision-makers and C-level executives and then conducting interviews and surveys to gain vital insights about the market. Simultaneously, extensive secondary research is done, and key secondary data is collected as part of this process. This secondary data is collected from various databases, industry journals, whitepapers, company annual reports, research publications, and other paid data sources and relevant literature. Company profiles which include strategies, new product developments, recent investments, major products and services, financials and business plans are sourced from the annual reports, SEC filings, industry associations to preserve the quality of the information being displayed. The findings from both the primary and the secondary research process combined go under further processing for market breakdown and forecasting.

The last phase is providing intelligence in the form of presentation, charts, graphics and other different formats helping the clients in a faster and efficient understanding of the market. Under this phase complete market engineering is involved which includes analyzing the collected data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting. The publisher has developed their market forecasting methodology that, in addition to the main market values, also takes into account other macroeconomic factors (global or local) that might have some bearing on the market under study. Taking all the necessary data, a robust forecast is developed using an algorithm that involves both static (multivariate) as well as dynamic (time-series) regression analysis. Special care is taken to make sure their algorithm passes the necessary statistical tests, and the mean prediction for future years obtained is reliable with a very high confidence level. Following data validation, the analysts begin to write the report presenting insights with the help of charts, graphs, and tables.

 

Loading
LOADING...

Adroll
adroll